BioMarin Pharmaceutical (BMRN) Earnings Date, Estimates & Call Transcripts $70.55 +0.69 (+0.99%) (As of 09/17/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 6EstimatedActual EPS (Aug. 5) $0.77 Beat By $0.39 Consensus EPS (Aug. 5) $0.38 Get BioMarin Pharmaceutical Earnings AlertsEnter your email address below to receive the latest news and earnings results for BMRN and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueBMRN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BMRN Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad InvestorPlaceWhy Are Buffett, Bezos, and Musk Fleeing Tech? Here's What To Do Now...The financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumping their tech stocks at a pace we've never seen before. What do they know that's pushing them out? One that Fortune is calling:"The Great Cash Out".Click here to get the details now. BioMarin Pharmaceutical Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20242$0.36$0.36$0.36 Q2 20242$0.36$0.61$0.49 Q3 20243$0.53$0.71$0.65 Q4 20243$0.55$0.71$0.63 FY 202410$1.80$2.39$2.12 Q1 20253$0.49$0.71$0.59 Q2 20253$0.61$0.83$0.75 Q3 20253$0.63$0.85$0.77 Q4 20253$0.66$0.87$0.79 FY 202512$2.39$3.26$2.90 Q1 20261$0.70$0.70$0.70 Q2 20261$0.73$0.73$0.73 BMRN Earnings Date and InformationBioMarin Pharmaceutical last issued its quarterly earnings data on August 5th, 2024. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.39. The business had revenue of $712.03 million for the quarter, compared to analysts' expectations of $660.51 million. BioMarin Pharmaceutical has generated $1.07 earnings per share over the last year ($1.07 diluted earnings per share) and currently has a price-to-earnings ratio of 65.9. Earnings for BioMarin Pharmaceutical are expected to grow by 35.42% in the coming year, from $2.40 to $3.25 per share. BioMarin Pharmaceutical has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off prior year's report dates.Read More BioMarin Pharmaceutical Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/6/2024(Estimated)------- 8/5/2024Q2 2024$0.38$0.77+$0.39$0.99$660.51 million$712.03 million4/24/2024Q1 2024$0.37$0.49+$0.12$0.52$649.75 million$648.83 million 2/22/2024Q4 2023$0.4450$0.49+$0.0450$0.41$639.53 million$646.21 million 11/1/2023Q3 2023$0.28$0.26($0.02)$0.31$603.51 million$581.33 million 7/31/2023Q2 2023$0.24$0.34+$0.10$0.39$591.46 million$595.28 million 4/26/2023Q1 2023$0.24$0.39+$0.15$0.51$572.53 million$596.42 million Get the Latest News and Ratings for BMRN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. 2/27/2023Q4 2022$0.12$0.11($0.01)$0.22$533.88 million$537.54 million 10/26/2022Q3 2022$0.12$0.16+$0.04$0.36$516.03 million$505.30 million 8/3/2022Q2 2022$0.20$0.33+$0.13$0.51$514.18 million$533.80 million 4/27/2022Q1 2022$0.15$0.31+$0.16($0.01)$505.11 million$519.36 million 2/23/2022Q4 2021($0.22)($0.21)+$0.01($0.10)$442.38 million$449.81 million 10/26/2021Q3 2021($0.25)($0.20)+$0.05$0.14$435.29 million$408.74 million 7/27/2021Q2 2021($0.11)$0.07+$0.18$0.39$448.84 million$501.69 million 4/28/2021Q1 2021$0.07$0.09+$0.02$0.49$445.44 million$486.03 million 2/25/2021Q4 2020($0.06)$0.12+$0.18($0.22)$447.17 million$452.12 million 11/5/2020Q3 2020($0.01)$4.01+$4.02($3.43)$454.64 million$476.78 million 8/4/2020Q2 2020($0.10)$0.07+$0.17$0.30$418.02 million$429.49 million 4/29/2020Q1 2020$0.12$0.44+$0.32$0.32$468.77 million$502.07 million 2/26/2020Q4$0.01$0.08+$0.07$0.10$461.88 million$454.44 million 10/23/2019Q3$0.06$0.31+$0.25$0.14$455.78 million$461.10 million BioMarin Pharmaceutical Earnings - Frequently Asked Questions When is BioMarin Pharmaceutical's earnings date? BioMarin Pharmaceutical has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates. Learn more on BMRN's earnings history. What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical issued an update on its FY 2027 earnings guidance on Thursday, September, 5th. The company issued revenue guidance of $4.0 billion-$4.0 billion. Did BioMarin Pharmaceutical beat their earnings estimates last quarter? In the previous quarter, BioMarin Pharmaceutical (NASDAQ:BMRN) reported $0.77 earnings per share (EPS) to beat the analysts' consensus estimate of $0.38 by $0.39. Learn more on analysts' earnings estimate vs. BMRN's actual earnings. How much revenue does BioMarin Pharmaceutical generate each year? BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded annual revenue of $2.59 billion. How much profit does BioMarin Pharmaceutical generate each year? BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded net income of $167.65 million. BMRN has generated $1.07 earnings per share over the last four quarters. What is BioMarin Pharmaceutical's price-to-earnings ratio? BioMarin Pharmaceutical (NASDAQ:BMRN) has a trailing price-to-earnings ratio of 65.94 and a forward price-to-earnings ratio of 29.40. The price/earnings-to-growth ratio is 1.03. What is BioMarin Pharmaceutical's EPS forecast for next year? BioMarin Pharmaceutical's earnings are expected to grow from $2.40 per share to $3.25 per share in the next year, which is a 35.42% increase. More Earnings Resources from MarketBeat Related Companies: TEVA Earnings Date SRPT Earnings Date VYGR Earnings Date ALNY Earnings Date BIIB Earnings Date UTHR Earnings Date INCY Earnings Date NBIX Earnings Date EXAS Earnings Date RGEN Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings This page (NASDAQ:BMRN) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersJoin Training: Target 1,000% with One $0.99 election tradeMillionaire Trader Nate Bear is hosting a FREE TRAINING TODAY, where he'll demonstrate how his unique trading ...Monument Traders Alliance | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredI’m giving you the name of this investment for freeNow that the Federal Reserve lowered interest rates, this investment could easily go up 50%.Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredThe #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
